SenoRx, a medical device maker offering an FDA approved biopsy system to detect breast cancer, filed an S-1 registration statement with the SEC on Thursday. The California based company generated $20 million in sales over the last 12 months, but has yet to turn profitable on the bottom line. Banc of America Securities and Citigroup have been selected to lead manage the deal. Terms and timing have yet to be announced.
